"" Novozymes Surpasses Expectations with Strong Q2 Results
Novozymes AS stock surged 8.0% to DKK 445.6 in intraday trading after the Danish biosolutions maker reported second-quarter results above estimates. The company also raised its full-year guidance and announced a share buyback program worth EUR 1 billion.
According to Novozymes, second-quarter adjusted EBITDA came in at €419.2 million, beating the consensus estimate of €412.8 million. Organic growth reached 9%, exceeding the 7.4% estimate.
The company's positive earnings report was compounded by the announcement of a share buyback program, which is expected to commence in the second half of 2026 and run through 2029. This move is seen as a clear signal of management's confidence in the company's cash generation capacity.
Novozymes also confirmed its agreement to acquire the remaining 77% stake in Australian biotech MicroBioGen, expanding its footprint in industrial yeast strain technology.
The stock touched a new 52-week high of DKK 457 intraday, reflecting the scale of the positive surprise. The company's strong Q2 results, combined with the buyback announcement and MicroBioGen acquisition, created a powerful confluence of catalysts that drove a significant gain in the stock.
Key Takeaways:
- Novozymes AS stock surged 8.0% to DKK 445.6 after beating Q2 estimates
- The company raised its full-year guidance and announced a share buyback program worth EUR 1 billion
- Novozymes confirmed its agreement to acquire the remaining 77% stake in Australian biotech MicroBioGen
** ** image_prompt: bold graphic of the Novozymes logo
